Hikma taps Arestat, a formulation technology for protein- and peptide-based drugs, to develop an injectable medicine, ahead of filing for US FDA approval.
Civica and Hikma agree a manufacture and supply partnership to increase access to 14 essential sterile injectable medicines for the US hospital network.